CLOs on the Move

Armetheon

www.armetheon.com

 
Armetheon, Inc. is a privately held San Francisco Bay area-based biopharmaceutical company with late-stage clinical drug candidates in development for cardiovascular diseases. The company was founded in 2011 by experienced biotech entrepreneurs and drug developers. Armetheon’s two late-stage small molecule drug candidates are for use in the areas of oral anti-coagulation and anti-arrhythmia for atrial fibrillation. The company was founded with the idea that drug innovations can happen by building on the success of proven medications. We create solutions that are within the same class of medication and that utilize the same mechanism of action as existing therapies. This development approach has the ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.armetheon.com
  • 3375 Scott Blvd Suite 306
    Santa Clara, CA USA 95054
  • Phone: 650.646.3898

Executives

Name Title Contact Details

Similar Companies

CommonHealth

CommonHealth comprises Altum, Carbon, CommonHealth London, CommonHealth Paris, Conectics, Earthborn, EvoLogue, Ferguson, HLS, MBS/Vox, ProCom, Qi, Solara and Valos.

M Jacobson Usa

M Jacobson Usa is a Los Angeles, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

LL Tech Inc

LL Tech Inc is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Haemonetics

We believe that through proper blood management, our products and services can help our commercial plasma and blood center customers optimize their collection processes. We seek to help ensure a continual supply of high-quality plasma for biopharmaceuticals and blood components for therapeutic use at optimal costs, along with better blood management processes. Working with our hospital customers, we seek to prevent a blood transfusion to the patient who doesn’t need one, or, if a transfusion is necessary, to ensure the transfusion of the right blood product, at the right time, in the right dose to the patient who does.